SCHEMBL490962

SCHEMBL490962

C1=CO[C](c2ccccc2)O1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.47
RAB9A P51151 3/20 0.38
NPC1 O15118 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAPK1 P28482 3/20 0.36
TAAR1 Q96RJ0 2/20 0.36
LMNA P02545 2/20 0.35
HTT P42858 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
NOTUM Q6P988 2/20 0.35
CYP1A2 P05177 1/20 0.35
MAPT P10636 1/20 0.35
CYP3A4 P08684 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MMP3 P08254 1/20 0.35
BCL2L1 Q07817 1/20 0.35
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
BACE1 P56817 1/20 0.33
CA1 P00915 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1747905 0.75 ALDH1A1 (0.47) ALDH1A1RAB9ANPC1SMN1; SMN2MAPK1
Biphenyl SCHEMBL8502577 0.68 ALDH1A1 (0.82) ALDH1A1RAB9ANPC1SMN1; SMN2MAPK1
Biphenyl SCHEMBL27573866 0.68 ALDH1A1 (0.82) ALDH1A1RAB9ANPC1SMN1; SMN2MAPK1
SCHEMBL216526 0.68 ALDH1A1 (0.67) ALDH1A1RAB9ANPC1MAPK1TAAR1
Biphenyl SCHEMBL27813018 0.67 ALDH1A1 (0.64) ALDH1A1RAB9ANPC1SMN1; SMN2MAPK1
SCHEMBL30108088 0.67 ALDH1A1 (1.00) ALDH1A1RAB9ANPC1SMN1; SMN2MAPK1
Biphenyl SCHEMBL4002609 0.67 ALDH1A1 (1.00) ALDH1A1RAB9ANPC1SMN1; SMN2MAPK1
Biphenyl SCHEMBL28890607 0.67 ALDH1A1 (1.00) ALDH1A1RAB9ANPC1SMN1; SMN2MAPK1
Biphenyl SCHEMBL164 0.67 ALDH1A1 (1.00) ALDH1A1RAB9ANPC1SMN1; SMN2MAPK1
Biphenyl SCHEMBL1358618 0.67 ALDH1A1 (1.00) ALDH1A1RAB9ANPC1SMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110191639-A Substituted sulfonamides for combating animal pests 拜耳公司 2019-08-30 CN claimed
US-20080161312-A1 Derivatives of Pyrrolo-Pyrazines Having a Kinase Inhibitory Activity and Their Biological Applications CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) 2008-07-03 US claimed
EP-1527077-A2 PYRROLOPYRAZINES AS KINASE INHIBITORS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2005-05-04 EP claimed
WO-2004016614-A2 PYRROLOPYRAZINES AS KINASE INHIBITORS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) 2004-02-26 WO claimed
EP-1388541-A1 Pyrrolopyrazines as kinase inhibitors CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2004-02-11 EP claimed
WO-2023237097-A1 19-NOR-C3,3-DISUBSTITUTED C21-AZACYCLO-SUBSTITUTED STEROID AND METHOD FOR USING SAME 山东绿叶制药有限公司 2023-12-14 WO disclosed
CN-113994970-B Substituted sulfonamides for combating animal pests 拜耳公司 2023-05-12 CN disclosed
CN-110191639-A Substituted sulfonamides for combating animal pests 拜耳公司 2019-08-30 CN disclosed
US-8106050-B2 6-[1-(4-Chlorophenyl)-1-cyclopropyl][5H]pyrrolo[2,3-b]pyrazine; cyclin-dependent kinases and glycogen synthase kinase-3 inhibitor; antiproliferative, anticarcinogenic agent; neurodegenerative disorders; controlling the cell cycle apoptosis, neuronal functions, transcription and exocytosis CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) 2012-01-31 US disclosed
EP-1807084-B1 USE OF PYRROLOPYRAZINE DERIVATIVES FOR THE PRODUCTION OF MEDICAMENTS FOR THE TREATMENT OF MUCOVISCIDOSIS CENTRE NAT RECH SCIENT (FR) 2010-12-15 EP disclosed
US-20090048260-A1 Use of pyrrolopyrazine derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells UNIVERSITE DE POITIERS (FR) 2009-02-19 US disclosed
US-20080161312-A1 Derivatives of Pyrrolo-Pyrazines Having a Kinase Inhibitory Activity and Their Biological Applications CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) 2008-07-03 US disclosed
EP-1807084-A2 USE OF PYRROLOPYRAZINE DERIVATIVES FOR THE PRODUCTION OF MEDICAMENTS FOR THE TREATMENT OF MUCOVISCIDOSIS AND DISEASES RELATED TO PROTEIN ADDRESSING ERRORS IN CELLS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2007-07-18 EP disclosed
WO-2006042950-A2 USE OF PYRROLOPYRAZINE DERIVATIVES FOR THE PRODUCTION OF MEDICAMENTS FOR THE TREATMENT OF MUCOVISCIDOSIS AND DISEASES RELATED TO PROTEIN ADDRESSING ERRORS IN CELLS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2006-04-27 WO disclosed
EP-1527077-A2 PYRROLOPYRAZINES AS KINASE INHIBITORS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2005-05-04 EP disclosed
WO-2004016614-A2 PYRROLOPYRAZINES AS KINASE INHIBITORS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) 2004-02-26 WO disclosed
EP-1388541-A1 Pyrrolopyrazines as kinase inhibitors CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2004-02-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161312-A1 Derivatives of Pyrrolo-Pyrazines Having a Kinase Inhibitory Activity and Their Biological Applications CDK2, PLK2, CDK5 ALDH1A1 1812/4885RAB9A 2889/4885NPC1 2937/4885
US-20090048260-A1 Use of pyrrolopyrazine derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells HRH2, HRH1, HRH4 ALDH1A1 1645/4885RAB9A 3436/4885NPC1 2345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.